RAS抑制剂在代谢功能障碍相关脂肪性肝病管理中的价值研究进展

摘要/Abstract

摘要： 代谢功能障碍相关脂肪性肝病(MASLD)的患病率逐年攀升,已成为全球最常见的慢性肝病。目前缺乏有效的治疗药物。肾素-血管紧张素系统(RAS)抑制剂包括血管紧张素转换酶抑制剂(ACEIs)/血管紧张素受体阻滞剂(ARBs),多用于高血压、心血管系统疾病及肾脏疾病的治疗。近年来,有研究提出ACEIs/ARBs可用于MASLD,以改善肝脏相关不良结局。本文旨在系统阐述ACEIs/ARBs治疗MASLD的基础机制、临床价值及研究进展。

任昱霖, 宋雨泽, 娄子璇, 杨涛, 温晓玉. RAS抑制剂在代谢功能障碍相关脂肪性肝病管理中的价值研究进展[J]. 肝脏, 2026, 31(5): 606-609.

/ 推荐

参考文献

[1] Rinella M E, Neuschwander-Tetri B A, Siddiqui M S, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5):1797-1835.
[2] 中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 中华肝脏病杂志, 2024, 32(5):418-434.
[3] Chen V L, Morgan T R, Rotman Y, et al. Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease:October 2024 updates to AASLD Practice Guidance[J]. Hepatology, 2025, 81(1):312-320.
[4] Bansal M B, Patton H, Morgan T R, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis:November 2025 updates to AASLD Practice Guidance[J]. Hepatology, 2026, 83(5):1326-1340.
[5] Seidita A, Buscemi C, Di Liberto D, et al. Angiotensin-converting enzyme inhibitors to prevent liver fibrosis in metabolic dysfunction-associated steatotic liver disease:scientific speculation or an opportunity to improve real Clinical Practice?[J]. Int J Mol Sci, 2025, 26(24):11782.
[6] Zhang Y, Xing M, Meng F, et al. The mechanical mechanism of angiotensin Ⅱ induced activation of hepatic stellate cells promoting portal hypertension[J]. Eur J Cell Biol, 2024, 103(2):151427.
[7] Kuang X, Naiki-Ito A, Kawamura H, et al. Hepatic stellate cell inhibition by angiotensin Ⅱ receptor blocker mitigates liver injury and fibrosis via NF-κB-galectin-3 suppression in a rat nonalcoholic steatohepatitis model[J]. Arch Toxicol, 2025, 99(8):3393-3412.
[8] Wang C H, Liu H M, Chang Z Y, et al. Losartan prevents hepatic steatosis and macrophage polarization by inhibiting HIF-1α in a murine model of NAFLD[J]. Int J Mol Sci, 2021, 22(15):7841.
[9] Godoy-Lugo J A, Thorwald M A, Mendez D A, et al. Glucose increases hepatic mitochondrial antioxidant enzyme activities in insulin resistant rats following chronic angiotensin receptor blockade[J]. Int J Mol Sci, 2022, 23(18):10897.
[10] Bentanachs R, Ramírez-Carrasco P, Braster B, et al. Telmisartan reverses hepatic steatosis via PCK1 upregulation:a novel PPAR-independent mechanism in experimental models of MASLD[J]. Pharmacol Res, 2025, 218:107860.
[11] Sturzeneker M C S, de Noronha L, Olandoski M, et al. Ramipril significantly attenuates the development of non-alcoholic steatohepatitis in hyperlipidaemic rabbits[J]. Am J Cardiovasc Dis, 2019, 9(2):8-17.
[12] Ryu T, Seo Y J, Lee J, et al. Class-specific effects of ARBs versus ACE inhibitors on survival and cardiovascular outcomes in MASLD[J]. Int J Mol Sci, 2025, 26(20):10061.
[13] Zhang X, Wong G L, Yip T C, et al. Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease[J]. Hepatology, 2022, 76(2):469-482.
[14] Ng W H, Yeo Y H, Kim H, et al. Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases:target trial emulation using real-world data[J]. Hepatology, 2026, 83(2):333-343.
[15] McPherson S, Wilkinson N, Tiniakos D, et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis[J]. PLos One, 2017, 12(4):e0175717.
[16] Vos M B, Van Natta M L, Blondet N M, et al. Randomized placebo-controlled trial of losartan for pediatric NAFLD[J]. Hepatology, 2022, 76(2):429-444.
[17] Newton K P, Lavine J E, Wilson L, et al. Alanine aminotransferase and gamma-glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis[J]. Hepatology, 2021, 73(3):937-951.
[18] Arsik I, Frediani J K, Frezza D, et al. Alanine aminotransferase as a monitoring biomarker in children with nonalcoholic fatty liver disease:a secondary analysis using TONIC trial data[J]. Children (Basel), 2018, 5(6):64.
[19] Kim K M, Roh J H, Lee S, et al. Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease[J]. Sci Rep, 2021, 11(1):2884.
[20] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3):492-542.
[21] Fujinaga Y, Kawaratani H, Kaya D, et al. Effective combination therapy of angiotensin-II receptor blocker and rifaximin for hepatic fibrosis in rat model of nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2020, 21(15):5589.